Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

@inproceedings{Ascierto2010RegulatoryTC,
  title={Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment},
  author={Paolo Antonio Ascierto and Maria Napolitano and Egidio Celentano and Ester Simeone and Giusy Gentilcore and Antonio Daponte and Mariaelena Capone and Corrado Carac{\`o} and Rosa Calemma and Gerardo Beneduce and Margherita Cerrone and Vincenzo de Rosa and Giuseppe Palmieri and Giuseppe Castello and John Munn Kirkwood and Francesco M. Marincola and Nicola Mozzillo},
  booktitle={Journal of Translational Medicine},
  year={2010}
}
High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by measuring serum regulatory T cell (Treg), serum transforming growth factor-β (TGF-β), interleukin (IL)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose IFN-α 2b regimen. Patients with melanoma received IFN-α 2b… CONTINUE READING
19 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Blood reduction of circulating regulatory T cell (Treg) by intra venous high dose Interferon treatment in melanoma matients: preliminary results

  • E Simeone, M Napolitano, +10 authors Ascierto
  • Journal of Translational Medicine 2010,
  • 2007
Highly Influential
11 Excerpts

Prognostic significance of autoimmunity during treatment of melanoma with interferon

  • H Gogas, J Ioannovich, +12 authors JM Kirkwood
  • N Engl J Med
  • 2006
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…